Menopausal hormone therapy does not play a major role in left ventricular hypertrophy

Maturitas

Volumn 66, Issue 2, 2010, Pages 212-218

  Schwarz, Sabine ^a   Obst, Anne ^b   Schwahn, Christian ^b   Völzke, Henry ^b   Schmidt, Carsten O ^b   Dörr, Marcus ^b   Felix, Stephan B ^b   Dören, Martina ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Left ventricular hypertrophy; Left ventricular mass (index); Menopausal hormone therapy

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; ARTICLE; BODY WEIGHT; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HORMONAL THERAPY; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; POSTMENOPAUSE; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

AGED; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; LONGITUDINAL STUDIES; MIDDLE AGED;

EID: 77952740853     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2010.03.014     Document Type: Article

References (41)

1. Levy D., Garrison R.J., Savage D.D., Kannel W.B., and Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322 (1990) 1561-1566
2. Vakili B.A., Okin P.M., and Devereux R.B. Prognostic implications of left ventricular hypertrophy. Am Heart J 141 (2001) 334-341
3. Liao Y., Cooper R.S., Mensah G.A., and McGee D.L. Left ventricular hypertrophy has a greater impact on survival in women than in men. Circulation 92 (1995) 805-810
4. Hayward C.S., Kelly R.P., and Collins P. The roles of gender, the menopause and hormone replacement on cardiovascular function. Cardiovasc Res 46 (2000) 28-49
5. Kuch B., Muscholl M., Luchner A., Döring A., Riegger G.A., Schunkert H., et al. Gender specific differences in left ventricular adaptation to obesity and hypertension. J Hum Hypertens 12 (1998) 685-691
6. Barrett-Connor E., and Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 19 (1998) 55-72
7. Nelson H.D., Humphrey L.L., Nygren P., Teutsch S.M., and Allan J.D. Postmenopausal hormone replacement therapy: scientific review. JAMA 288 (2002) 872-881
8. Manolio T.A., Furberg C.D., Shemanski L., Psaty B.M., O'Leary D.H., Tracy R.P., et al. Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. The CHS Collaborative Research Group. Circulation 88 (1993) 2163-2171
9. Pines A., Fisman E.Z., Shapira I., Drory Y., Weiss A., Eckstein N., et al. Exercise echocardiography in postmenopausal hormone users with mild systemic hypertension. Am J Cardiol 78 (1996) 1385-1389
10. Lim W.K., Wren B., Jepson N., Roy S., and Caplan G. Effect of hormone replacement therapy on left ventricular hypertrophy. Am J Cardiol 83 (1999) 1132-1134
11. Light K.C., Hinderliter A.L., West S.G., Grewen K.M., Steege J.F., Sherwood A., et al. Hormone replacement improves hemodynamic profile and left ventricular geometry in hypertensive and normotensive postmenopausal women. J Hypertens 19 (2001) 269-278
12. Oberman A., Prineas R.J., Larson J.C., LaCroix A., and Lasser N.L. Prevalence and determinants of electrocardiographic left ventricular hypertrophy among a multiethnic population of postmenopausal women (The Women's Health Initiative). Am J Cardiol 97 (2006) 512-519
13. Modena M.G., Muia N., Aveta P., Molinari R., and Rossi R. Effects of transdermal 17beta-estradiol on left ventricular anatomy and performance in hypertensive women. Hypertension 34 (1999) 1041-1046
14. Modena M.G., Molinari R., Muia N., Castelli A., Pala F., and Rossi R. Double-blind randomized placebo-controlled study of transdermal estrogen replacement therapy on hypertensive postmenopausal women. Am J Hypertens 12 (1999) 1000-1008
15. Snabes M.C., Payne J.P., Kopelen H.A., Dunn J.K., Young R.L., and Zoghbi W.A. Physiologic estradiol replacement therapy and cardiac structure and function in normal postmenopausal women: a randomized, double-blind, placebo-controlled, crossover trial. Obstet Gynecol 89 (1997) 332-339
16. Vogelvang T.E., Mijatovic V., Kamp O., Netelenbos J.C., Neele S.J., Pines A., et al. Neither long-term treatment with raloxifene nor hormone replacement therapy modulate cardiac function in healthy postmenopausal women: two randomized, placebo-controlled, 2-year studies. Am J Obstet Gynecol 186 (2002) 729-736
17. John U., Greiner B., Hensel E., Lüdemann J., Piek M., Sauer S., et al. Study of health in Pomerania (SHIP): a health examination survey in an east German region: objectives and design. Soz Präventivmed 46 (2001) 186-194
18. Fricke U., and Günther J. Anatomisch-therapeutisch-chemische Klassifikation mit Tagesdosen für den deutschen Arzneimittelmarkt [anatomical therapeutic chemical (ATC) classification index with defined daily dose (DDD)] (2002), Wissenschaftliches Institut der AOK (WIdo), Bonn
19. Reichek N., and Devereux R.B. Left ventricular hypertrophy: relationship of anatomic, echocardiographic and electrocardiographic findings. Circulation 63 (1981) 1391-1398
20. Devereux R.B., Alonso D.R., Lutas E.M., Gottlieb G.J., Campo E., Sachs I., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57 (1986) 450-458
21. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18 (2005) 1440-1463
22. Schafer J.L., and Graham J.W. Missing data: our view of the state of the art. Psychol Methods 7 (2002) 147-177
23. Little R.J.A., and Rubin D.B. Statistical analysis with missing data. 2nd ed. (2002), John Wiley & Sons, Inc., New Jersey
24. Matthews K.A., Kuller L.H., Wing R.R., Meilahn E.N., and Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers?. Am J Epidemiol 143 (1996) 971-978
25. Du Y., Dören M., Melchert H.U., Scheidt-Nave C., and Knopf H. Differences in menopausal hormone therapy use among women in Germany between 1998 and 2003. BMC Womens Health 7 (2007) 19
26. Vasan R.S., Glazer N.L., Felix J.F., Lieb W., Wild P.S., Felix S.B., et al. Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. JAMA 302 (2009) 168-178
27. Völzke H., Stritzke J., Kuch B., Schmidt C.O., Lüdemann J., Döring A., et al. Regional differences in the prevalence of left ventricular hypertrophy within Germany. Eur J Cardiovasc Prev Rehabil 16 (2009) 392-400
28. Friedrich N, Aumann N, Dörr M, Felix SB, Nauck M, Wallaschofski H, et al. Lack of association between insulin-like growth factor-1 or insulin-like growth factor-binding protein-3 and left ventricular hypertrophy: results of the study of health in Pomerania. J Hypertens 2009; in press.
29. Meisinger C., Heier M., Völzke H., Löwel H., Mitusch R., Hense H.W., et al. Regional disparities of hypertension prevalence and management within Germany. J Hypertens 24 (2006) 293-299
30. Gosse P., Jullien V., Jarnier P., Lemetayer P.J., and Clementy J. Echogardiographic definition of left ventricular hypertrophy in the hypertensive: which method of indexation of left ventricular mass?. J Hum Hypertens 13 (1999) 505-509
31. Cuspidi C., Meani S., Negri F., Guidici V., Valerio C., Sala C., et al. Indexation of left ventricular mass to body surface area and height to allometric power of 2.7: is the difference limited to obese hypertensives?. J Hum Hypertens 23 (2009) 728-734
32. de Simone G., Kizer J.R., Chinali M., Roman M.J., Bella J.N., Best L.G., et al. Normalization for body size and population-attributable risk of left ventricular hypertrophy: the strong heart study. Am J Hypertens 18 (2005) 191-196
33. Kuch B., Hense H.W., Muscholl M., Bröckel U., Döring A., Riegger G.A.J., et al. Postmenopausal hormone replacement therapy and left ventricular mass and geometry. J Am Coll Cardiol 29 (1997) 297A [Abstract]
34. Donaldson C., Eder S., Baker C., Aronovitz M.J., Weiss A.D., Hall-Porter M., et al. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor dependent pathway that increases calcineurin degradation. Circ Res 104 (2009) 265-275
35. Patten R.D., Pòurati I., Aronovitz M.J., Alsheikh-Ali A., Eder S., Force T., et al. 17 beta-estradiol differentially affects left ventricular and cardiomyocyte hypertrophy following myocardial infarction and pressure overload. J Card Fail 14 (2008) 245-253
36. Watanabe T., Akishita M., He H., Miyahara Y., Nagano K., Nakaoka T., et al. 17β-estradiol inhibits cardiac fibroblast growth through both subtypes of estrogen receptor. Biochem Biophys Res Commun 311 (2003) 453-459
37. Goodman M.T., Nomura A.M., Wilkens L.R., and Kolonel L.N. Agreement between interview information and physician records on history of menopausal estrogen use. Am J Epidemiol 131 (1990) 815-825
38. Banks E., Beral V., Cameron R., Hogg A., Langley N., Barnes I., et al. Agreement between general practice prescription data and self-reported use of hormone replacement therapy and treatment for various illnesses. J Epidemiol Biostat 6 (2001) 357-363
39. Rosenbaum P.R., and Rubin D.B. The central role of the propensitiy score in observational studies for causal effects. Biometrika 70 (1983) 41-55
40. Shah B.R., Laupacis A., Hux J.E., and Austin P.C. Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol 58 (2005) 550-559
41. Stürmer T., Joshi M., Glynn R.J., Avorn J., Rothman K.J., and Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 59 (2006) 437-447